China has added two chemicals—4-piperidone and 1-Boc-4-piperidone—to its controlled fentanyl precursor list, effective July 20, 2025. The move aims to address US accusations that China is not doing enough to stop fentanyl flows, which have been entangled with broader trade disputes. Overseas chemical buyers should monitor how these new controls may affect supply chains for these intermediates and related downstream products.
Regulatory update
China's six government departments jointly announced the inclusion of 4-piperidone and 1-Boc-4-piperidone on the fentanyl precursor list, imposing strict controls. The new measures take effect on July 20, 2025. This follows a meeting between Chinese Public Security Minister Wang Xiaohong and new US Ambassador to China David Perdue on drug enforcement cooperation.
US-China dispute context
The Trump administration has accused Chinese chemical companies of supplying fentanyl raw materials to drug cartels, which then smuggle the drug into the US. Washington has used this issue to justify additional 20% tariffs on Chinese goods earlier this year. While the broader trade war tariffs were reduced from 145% to 55% in May 2025, the fentanyl-related tariffs remain in place.
China's position
China maintains that the US fentanyl crisis stems from domestic overprescription of painkillers and regulatory failures. "Fentanyl is America's problem, not China's problem. The responsibility lies with the US itself," said Chinese Foreign Ministry spokesperson Guo Jiakun on Tuesday. Beijing sees the new controls as a gesture of goodwill for cooperation.
What buyers should watch
Chemical importers and distributors should verify whether their supply chains involve 4-piperidone or 1-Boc-4-piperidone, as these are now subject to strict Chinese export controls. Companies sourcing these intermediates from China may face new licensing requirements and potential delays. The July 20 effective date leaves limited time for compliance adjustments.
China sourcing context
Trade tensions remain fluid. Presidents Trump and Xi Jinping have agreed to restart trade talks and discussed a possible meeting. Scholar Wu Xinbo from Fudan University noted that a Xi-Trump meeting could occur at the APEC summit in Seoul in late October 2025, but neither leader has confirmed attendance. Any progress on fentanyl controls could influence tariff negotiations.
Source: Read the original report | Published: June 26, 2025